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ABSTRACT
This nationwide study was conducted to assess the extent of adherence of primary-care physicians 
to the World Health Organization (WHO)-recommended guidelines on the use of oral rehydration 
therapy (ORT), antimicrobials, and prescribing of other drugs used in treating symptoms of acute 
diarrhoea in Bahrain. A questionnaire-based, cross-sectional survey was carried out in primary-care 
health centres. During a six-week survey period (15 August–30 September 2003), 328 (25.2%) com-
pleted questionnaires were returned from 17 of 20 health centres. In a sample of 300 patients, oral re-
hydration salts (ORS) solution was prescribed to 89.3% (n=268) patients; 12.3% received ORS alone, 
whereas 77% received ORS in combination with symptomatic drugs. Antimicrobials were prescribed to 
2% of the patients. In 11.4% of the cases, rehydration fluids and other drugs were given parenter-
ally. The mean number of drugs was 2.2+0.87 per prescription. In approximately one-third of the 
patients, three or more drugs were used. Primary-care physicians almost always adhered to the WHO 
guidelines with respect to ORT and antimicrobials. However, in several instances, ORT was pres-
cribed along with polypharmacy, including irrational use of drugs for symptomatic relief.  Effective 
health policies are needed to reduce the unnecessary burden on the healthcare system.
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INTRODUCTION
Acute diarrhoeal diseases are an important pub-
lic-health problem worldwide. Diarrhoea con-
tinues to be a major cause of hospitalization 
and death of young children and has major eco-
nomic consequences (1,2). In the United States 
alone,  an  estimated  211-375  million  episodes 
of acute diarrhoea occur each year, resulting in 
more than 900,000 hospitalizations and 6,000 
deaths (3). In developing countries, the rate of 
diarrhoeal illness is 2-3 times higher than that 
in developed countries (4), and most studies 
on acute diarrhoea carried out during the last 
decade were limited to children aged less than 
five years. These studies have mainly addressed 
the perceptions and practice of oral rehydra-
tion salts (ORS) solution therapy, prevalence 
of diarrhoea, social determinants of diarrhoea, 
and microbiological considerations of causative 
pathogens. Since the national guidelines for the 
management of acute diarrhoea have not yet 
been established in Bahrain, the treatment of 
diarrhoea is largely based on the World Health 
Organization (WHO)-recommended guidelines 
(2).  Acute  gastroenteritis  is  considered  one  of 
the common complaints in the primary-care set-
ting in Bahrain; nonetheless, its management 
has never been evaluated. This cross-sectional 
study evaluated the extent of adherence of pri-
mary-care physicians in Bahrain to the WHO-
recommended guidelines in terms of the use of 
ORS solution therapy, use of antimicrobials, and 




The Kingdom of Bahrain, with a population of 
650,604, is a group of islands located in the Ismaeel AY et al. Management of acute diarrhoea
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Arabian Gulf. The Directorate of Health Cen-
tres, which has a network of 20 well-structured 
primary-care health centres spread across the 
country, provides free curative and preventive care 
services to both citizens and expatriates, includ-
ing dispensing of essential drugs. In addition to 
medical services delivered at the morning ses-
sion, 10 of these health centres provide daily 
evening and night services for 3-8 hours. On a 
trial basis, one of these health centres currently 
provides health services on a 24-hour basis. The 
number of primary-care physicians in each of 
these health centres varies from four to eleven. 
Patients requiring special investigations and 
consultations with specialists or admission are 
referred to the Salmaniya Medical Complex which 
provides secondary-tertiary care. The Salmaniya 
Medical Complex also serves as a teaching and 
research centre for health professionals. Based 
on drug-prescribing patterns, a cross-sectional 
survey of self-reported practices of doctors in 
treating acute episodes of diarrhoea was carried 
out in the 20 primary-care health centres in Bah-
rain.
Source of data and study population
A questionnaire was used for collecting data dur-
ing 15 August–30 September 2003. All patients, 
attending the primary-care health centres, with 
acute diarrhoea during this period were includ-
ed as the sample for the study. Acute diarrhoea 
was defined as a passage of loose or watery stool, 
usually at least three times in a 24-hour period (2).
Questionnaire: A descriptive questionnaire was 
developed and pre-tested by primary-care phy-
sicians. The questionnaire consisted of the fol-
lowing components: (a) information about the 
physicians; (b) demographic characteristics of 
patients (age, gender, and nationality); (c) time 
elapsed between onset of diarrhoea and attend-
ing health centres in days; (d) frequency of passing 
stool per day; (e) consistency and nature of stool; 
(f) complaints of patients; (g) history of medica-
tions; (h) physical examinations of patients; (i) 
microbiological investigations; (j) management 
of diarrhoea with pharmacological (i.e. ORS so-
lution therapy and/or other therapeutic drugs) 
and non-pharmacological measures (i.e. assur-
ance, diet advice, education, increased intake of 
fluid, stopping medication in the case of iatro-
genic diarrhoea, sick leave/rest). 
The questionnaire was distributed to primary-care 
health centres through the office of Chief of Medi-
cal Services for Primary Health Care, Directorate 
of Health Centres/Primary Health Care, Ministry 
of Health. The primary-care physicians were 
requested to complete the questionnaire while 
examining patients complaining of acute diar-
rhoea.
This descriptive study used the WHO guidelines 
for evaluating the extent of adherence to treat-
ment: the adherence was broadly categorized 
into (a) adherence to history-taking and physical 
examinations, (b) adherence to rehydration 
principles, and (c) adherence to prescribing. 
Data were analyzed using the SPSS software (SPSS/
Pct, version 10.0). Descriptive statistics, such as 
percentage, mean, and standard deviations were 
used for describing the study variables.
RESULTS
During the six-week period of the study, 328 
(25.2%) completed questionnaires were returned. 
The number of questionnaires returned from 
17 of the 20 health centres ranged from 3 to 47 
(mean+SD=17.4+14.6) per health centre. Sev-
enty (37.8%) of 185 primary-care physicians 
participated in treating 328 episodes of diar-
rhoea. The number of patients with diarrhoeal 
episodes seen per physician was 4.7+3.9 (median 
4; range 1-20). Of the 328 patients with acute diar-
rhoeal episodes, 58.2% were male, and 90.9% 
were Bahrainis.  
The mean age of the patients with acute diar-
rhoea was 24.8+15.3 years with a median age of 
24 years (range 0.1-65 years). The distribution of 
the patients in the study population according 
to age was as follows: children <12  (22.4%), ad-
olescents 13-19 (13.8%), adults 20-44 (51.5%), 
middle-aged 45-59 (10.1%), and elderly >60 
(2.1%) years. The incidence of acute diarrhoea 
was most common in adult patients.
The characteristics of diarrhoea, findings of physi-
cal examinations, and laboratory investigations 
requested are shown in Table 1. The mean time 
elapsed between onset of diarrhoea and attending 
health centres was 2.2+1.9 days, and the mean 
frequency of passing stool per day was 5.0+2.6. 
Two hundred thirty-nine (72.9%) of the 328 
patients with acute diarrhoea complained of 
watery stools, and eight (2.4%) complained of 
bloody diarrhoea, whereas stool characteristics 
were not specified in 81 (24.7%) patients.  Based 
on the signs and symptoms of dehydration, the 
physical examinations revealed that only 48 
(14.6%) patients had mild-to-moderate dehydra-Ismaeel AY et al. Management of acute diarrhoea
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Table 1. Characteristics of diarrhoea, clinical and laboratory findings
Diarrhoea-related parameters  Number Percentage
Characteristics of stool
   Watery         239    72.9
   Blood mixed     8      2.4
   Not specified   81    24.7
Physical examinations
   Normal (non-dehydrated) 270    82.3
   Mild dehydration   45    13.7
   Moderate-severe dehydration     3      0.9
   Not specified   10      3.0
Laboratory investigations
   Routine stool examination    36    11.0
   Stool culture      3      0.9
   Routine stool examination and culture    10      3.0
   None of the above  230    70.1
   Not specified    47    14.9
Complaints
   Abdominal pain 146    44.5
   Vomiting   33    10.1
   Fever   10      3.0
   Abdominal pain + vomiting   61    18.6
   Abdominal pain + fever   27      8.2
   Vomiting + fever   12      3.7
   Abdominal pain + vomiting + fever   18      5.5
   None of the above   12      3.7
   Not specified     9      2.7
Time (days) elapsed between onset of diarrhoea
  and attending health centres (mean+SD) 2.2+1.9  (326)
Frequency of passing stool per day (mean+SD) 5.0+2.6  (320)
Figures in parentheses indicate the number of patients
tion, whereas 270 (82.3%) had no signs of de-
hydration. 
Of the 328 acute episodes of diarrhoea, 300 (91.5%) 
patients were on pharmacological intervention, 
and six (1.8%) were on non-pharmacological in-
terventions (assurance, education, dietary advice, 
fluid intake). In 22 (6.7%) cases, patients’ man-
agement was not specified.
The prescribing patterns for the treatment of 300 
episodes of diarrhoea are shown in Table 2. In 
a sample of 300 patients, ORS was prescribed 
to 89.3% (n=268); 12.3% received ORS alone, 
whereas 77% received ORS in combination with 
symptomatic drugs and/or intravenous fluids. 
The mean number of drugs per prescription was 
2.2+0.9, whereas the mean number of drugs per 
prescription containing three or more drugs was 
3.3+0.6 (Table 3). The categories of drugs prescribed 
for the treatment of acute diarrhoeal episodes 
are presented (Table 4). Rehydration fluids and 
other drugs were given parenterally in 11.4% of 
the cases. 
DISCUSSION
The main goal in the management of acute diar-
rhoea is to prevent dehydration (if there are no 
signs of dehydration), treat dehydration (when it 
is present), and prevent nutritional insufficiency, 
particularly in children, by feeding during and 
after diarrhoea (2). The first two objectives can 
be achieved with ORS solution therapy which is 
accepted as the gold standard to achieve clini-
cally-efficacious and cost-effective management Ismaeel AY et al. Management of acute diarrhoea
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Table 2. Prescribing patterns for treatment of 300 diarrhoeal episodes*
Prescribing pattern
Number of drugs 
Total Percentage

























































Total number 60 148 72 18 2 300 99.8
*Of 328 patients, 6 (1.8%) were on non-pharmacological interventions, and in 22 (6.7%), patients’ man-
agement was not specified; †Include tablets, suspensions/syrups/drops, pills, capsules, and injections 
IV=Intravenous fluid; ORS=Oral rehydration solution 
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Number of drugs/prescriptions (mean+SD)                                                             2.2 + 0.9
Number of >3 drugs/prescriptions  (mean+SD)                                                      3.3 + 0.6  
*Of 328 patients, 6 (1.8%) were on non-pharmacological interventions, and in 22 (6.7%), patients’ 
management was not specified; †Include tablets, suspensions/syrups/drops, capsules, injections, 
oral rehydration solution, and intravenous fluids  
of acute gastroenteritis (2,5). Unless the patient 
is comatose or severely dehydrated, ORS solu-
tion is recommended regardless of the causative 
agent and age of the patient (2,3) because ORS 
solution therapy is less expensive, often just as 
effective, and more practical than intravenous 
fluid (4). Our study revealed that 89.3% of the 
patients received ORS solution (12.3% received 
ORS alone, and 77% received ORS in combina-
tion with symptomatic drugs). The prescription 
rate of ORS solution in our study was compa-
rable with (6), and considerably higher (7,8-11) 
than the rates reported by previous primary care-
based studies from other countries. This find-
ing suggests that, in Bahrain, the primary-care 
physicians adhered to the WHO guidelines in 
the management of acute diarrhoea, particular-
ly with regard to the use of ORS solution ther-
apy. However, such practice was found in several 
instances to be marginalized by prescribing ir-
rational drugs used for symptomatic relief in 
acute diarrhoea.
Routine prescribing of antimicrobials to patients 
with acute diarrhoea should be discouraged, 
because: (a) the majority of cases of acute diar-
rhoea are due to viral and non-invasive bacterial 
infections (2,4,5); (b) the duration of mild, self-
limited diarrhoeal illness is not decreased by use 
of antimicrobials (2,4,5); (c) the irrational use 
of antimicrobials results in wasting of resources 
and risks adverse reactions (2) and can increase 
production of Shiga toxin by enterohaemor-
rhagic Escherichia coli O157:H7 (5) and cytole-
thal distending toxin by Campylobacter jejuni 
(12); and (d) it can lead to increased antimicro-Ismaeel AY et al. Management of acute diarrhoea
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Table 4. Drugs prescribed for treatment of 300 diarrhoeal episodes*
Type of drug Number Percentage
Fluid and electrolyte therapy
    Oral rehydration solution
    Intravenous fluid
        0.9 % sodium chloride
        0.18% sodium chloride + 4.3% dextrose
Antimicrobials
    Amoxycillin
    Cephalexin
    Metronidazole
Symptomatic drugs
    Antidiarrhoeals
    Antispasmodics
    Antipyretic/analgesic
    Antiemetics
    Prokinetic
    H2-receptor antagonist
    Antacids
    Antiflatulents    
Intramuscular injection
    Antispasmodics 
    Antiemetics
268
    8
    3
   3
   1



























*Of 328 patients, 6 (1.8%) were on non-pharmacological interventions, and in 22 (6.7%), patients’ 
management was not specified
Antidiarrhoeal=Loperamide; Antispasmodics=Fixed dose combination of chlordiazepoxide + clidini-
um bromide (Librax®), hyoscine butyl bromide (Buscopan®), fixed dose of methylscopolamine + buta-
barbital drops (Restropinal® drops); Antipyretic/analgesic=Paracetamol; Antiemetics=Promethazine 
(Phenergan®),  prochlorperazine  (stemetil®);  Prokinetic=Metoclopramide;  H2-receptor  antagonist= 
Ranitidine; Antiflatulents=Carminative mixture
bial resistance, particularly when the sensitivity 
and resistance patterns of the potential underly-
ing causative microorganism is not determined 
(2,5,13). We observed that antimicrobials were 
used conservatively at a rate of 2% (Table 4), 
which was significantly lower than the rates 
reported elsewhere (7,8-11), and conformed to 
the guideline recommendations (2,3,5).
The use of antidiarrhoeals is contraindicated 
in children due to concerns about toxicities 
(2,3,5,14). Withdrawal of loperamide syrup for-
mulation from Bahrain Drug Formulary by the 
mid-1990s reflects the awareness of health poli-
cy decision-makers. Although antidiarrhoeals, 
such as loperamide, have a limited role for symp-
tomatic relief in adults with acute diarrhoea (2), 
we observed that 7% of the patients with diar-
rhoea received loperamide as an adjunct ther-
apy (Table 4). However, loperamide should be 
considered only in adults who are not febrile or 
having bloody/mucoid diarrhoea.  
Prescription of prokinetic metoclopramide to 
patients with acute diarrhoea is a controversial 
issue. The use of prokinetics in 4.3% of the pa-
tients, with a potential to cause diarrhoea (15), 
cannot be justified (Table 4). We believe that 
metoclopramide is irrationally used, in particu-
lar, if it was indicated for its antiemetic effects 
in patients with gastroenteritis, since diarrhoea 
is one of the potential adverse effects of meto-
clopramide (16).
Antiemetics, such as promethazine (Phenergan®) 
and  prochlorperazine  (Stemetil®),  are  contra-
indicated, particularly in children with acute di-
arrhoea (2,5). This is because: (a) correction of 
dehydration per se stops vomiting and restores Ismaeel AY et al. Management of acute diarrhoea
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appetite (2); (b) sedation induced by these anti-
emetics may interfere with ORS solution thera-
py (2); and (c) a post-marketing surveillance has 
revealed that promethazine can produce poten-
tial fatal respiratory depression in children aged 
less than two years (17). We observed that an-
tiemetics were prescribed to 36 (12%) patients 
with acute diarrhoea (Table 4). Four (19%) of 
21 patients who were on promethazine therapy 
were children aged less than two years. The use of 
promethazine in infants has been restricted due 
to safety concerns (18). Moreover, four (26.7%) 
of 15 patients who were receiving prochlorpera-
zine were adults who received prochlorperazine 
intramuscularly. A high incidence of dystonias 
has been reported with intramuscular prochlor-
perazine (19,20).
Antimuscarinic-antispasmodics as symptomatic 
drugs were prescribed to 80.7% of drug-treated 
episodes of diarrhoea (Table 4). Despite their ef-
fectiveness, they are no longer considered appro-
priate for use in infantile colic (21). Restropinal® 
drops, a fixed-dose combination of methylsco-
polamine (antimuscarinic antispasmodic) and 
butabarbital was given to 35.3% (6/17) of the 
infants and to 40% (24/60) of the children aged 
1-12 year(s), in our survey. Sedation induced 
by butabarbital—a component of Restropinal®—
should be considered since it may interfere with 
the ingestion of ORS solution, as is the case with 
the sedative promethazine (Phenergan®). 
The relatively short-time interval between onset 
of acute diarrhoea and visiting health centres 
(2.2+1.9 days) and lack of dehydration in the 
vast majority of (n=270, 82.3%) patients in our 
study are important considerations (Table 1). 
Plausible  explanations  for  these  findings  may 
be related to: (a) a community awareness about 
diarrhoea and its hazards; (b) a well-organized 
network of primary-care health services; and (c) 
health-seeking behaviour of the population.
Characteristics of diarrhoea, especially low fre-
quency of passing stool per day and low propor-
tion of patients with dehydration or bloody diar-
rhoea (Table 1), suggest that the vast majority of 
cases of acute diarrhoea were mild and self-limi-
ted.  This  explains  why  requests  for  microbio-
logical investigations and other laboratory tests 
were judicious, and the physicians complied in 
general with the published guidelines (3-5). 
Polypharmacy practice is well-known to be asso-
ciated with drug-related adverse reactions, medi-
cation errors, clinically significant drug inter-
actions, and an increased risk for admission of 
patients (22). Based on the drug-prescribing pat-
terns, we observed that polypharmacy, defined 
as prescriptions containing three or more drugs, 
comprised one-third of the cases, with a mean 
value of 3.3+0.6 drugs per prescription (Table 3). 
This polypharmacy practice seems to be related 
to free medical services, including dispensing 
essential drugs (23).
A few caveats on the study design and inter-
pretation of the results are to be considered. To 
what extent the observed findings of the study 
are generalizable and reflect a nationwide prac-
tice is uncertain. Also, how the adherence to the 
treatment guidelines influenced the outcomes, 
such as treatment-failure rate, mortality, and 
adverse events from medications, need to be ex-
plored. This study was a survey of self-reported 
practices of doctors in the management of diar-
rhoea. Their actual practices may not always be 
the same as reported in the questionnaire. The 
rigorous WHO guidelines for the treatment of 
diarrhoea may not always be appropriate due to 
the complexity of some diarrhoea cases. The ap-
propriateness of antimicrobials prescribing can-
not be assessed without stool culture results.  
However, based on the findings of the study, it 
can be concluded that primary-care physicians 
well adhered to the WHO guidelines with respect 
to the use of ORT and antimicrobials. In several 
instances, although ORT was used, polypharmacy 
and prescribing of irrational symptomatic drugs 
were also observed. The findings suggest that ef-
fective health policies are needed to reduce the 
unnecessary burden on the healthcare system. 
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